Proteinuria predicts 10-year cancer-related mortality in patients with type 2 diabetes

被引:11
作者
Yu, Tse-Ya [1 ]
Li, Hung-Yuan [2 ]
Jiang, Yi-Der [2 ]
Chang, Tien-Jyun [2 ]
Wei, Jung-Nan [3 ]
Chuang, Lee-Ming [2 ,4 ,5 ]
机构
[1] Publ Hlth Ctr Longci Dist, Tainan, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[3] Chia Nan Univ Pharm & Sci, Tainan, Taiwan
[4] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 10764, Taiwan
[5] Natl Taiwan Univ, Sch Publ Hlth, Grad Inst Prevent Med, Taipei 10764, Taiwan
关键词
Proteinuria; Cancer; Mortality; URINARY ALBUMIN EXCRETION; CHRONIC KIDNEY-DISEASE; ANGIOTENSIN-RECEPTOR BLOCKADE; NONCARDIOVASCULAR MORTALITY; LARGE COHORT; ALL-CAUSE; RISK; MICROALBUMINURIA; ASSOCIATION; INFLAMMATION;
D O I
10.1016/j.jdiacomp.2012.11.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: We conducted a cohort study to determine if proteinuria predicts cancer-related mortality in type 2 diabetic subjects. Methods: Between July 1996 and June 2003, we enrolled 646 type 2 diabetic subjects. Participants were followed-up until December 31, 2008. The vital status was ascertained by linking records with computerized death certificates in Taiwan. Results: During a median follow-up of 10.4 years, 158 subjects had died, including 59 from cancers. Subjects with proteinuria had a hazard ratio (HR) of 2.77 (95% CI 1.82-4.21) for all-cause mortality and 1.99 (95% CI 1.00-3.94) for cancer-related mortality after adjustment for demographic factors and medical conditions. Specifically, proteinuria showed a trend of increased colon cancer death. The presence of proteinuria significantly improved the predictive ability of cancer-related mortality (increase in concordance statistics or area under the ROC curve = 0.03). Patients with both proteinuria and estimated glomerular filtration rate <60 ml/min per 1.73 m(2) showed higher HR for all-cause mortality than patients with proteinuria only (adjusted HRs (95% CI), 4.01 (2.42-6.67) vs. 2.69 (1.51-4.79), both p<0.01). Conclusions: Proteinuria can predict 10-year all-cause and cancer-related mortalities independently in type 2 diabetic subjects, over and above the established risk factors associated with type 2 diabetes. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:201 / 207
页数:7
相关论文
共 37 条
[2]   Antihypertensives as novel antineoplastics: Angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma - Discussion [J].
Brennan, Murray F. ;
Riall, Taylor S. ;
Nealon, William H. ;
Arafat, Hwyda A. .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2007, 204 (05) :1005-1006
[3]   Risk of cancer in a large cohort of U.S. veterans with diabetes [J].
Atchison, Elizabeth A. ;
Gridley, Gloria ;
Carreon, J. Daniel ;
Leitzmann, Michael F. ;
McGlynn, Katherine A. .
INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (03) :635-643
[4]   Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes Mellitus A Systematic Review and Meta-analysis [J].
Barone, Bethany B. ;
Yeh, Hsin-Chieh ;
Snyder, Claire F. ;
Peairs, Kimberly S. ;
Stein, Kelly B. ;
Derr, Rachel L. ;
Wolff, Antonio C. ;
Brancati, Frederick L. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (23) :2754-2764
[5]   Angiotensin Receptor Blockade and Risk of Cancer in Type 2 Diabetes Mellitus: A Nationwide Case-Control Study [J].
Chang, Chia-Hsuin ;
Lin, Jou-Wei ;
Wu, Li-Chiu ;
Lai, Mei-Shu .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (22) :3001-3007
[6]   Inflammation and cancer [J].
Coussens, LM ;
Werb, Z .
NATURE, 2002, 420 (6917) :860-867
[7]   Angiotensin receptors: a new role in cancer? [J].
Deshayes, F ;
Nahmias, C .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2005, 16 (07) :293-299
[8]  
Erlinger TP, 2004, CANCER EPIDEM BIOMAR, V13, P1052
[9]   Kidney function as a predictor of noncardiovascular mortality [J].
Fried, LF ;
Katz, R ;
Sarnak, MJ ;
Shlipak, MG ;
Chaves, PHM ;
Jenny, NS ;
Stehman-Breen, C ;
Gillen, D ;
Bleyer, AJ ;
Hirsch, C ;
Siscovick, D ;
Newman, AB .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (12) :3728-3735
[10]   Telmisartan is a potent target for prevention and treatment in human prostate cancer [J].
Funao, Kiyoaki ;
Matsuyama, Masahide ;
Kawahito, Yutaka ;
Sano, Hajime ;
Chargui, Jamel ;
Touraine, Jean-Louis ;
Nakatani, Tatsuya ;
Yoshimura, Rikio .
ONCOLOGY REPORTS, 2008, 20 (02) :295-300